Lilac Biosciences and Soin Neuroscience publish RNA biomarker review for neuropathic pain
Lilac Biosciences and Soin Neuroscience map an RNA biomarker path for neuropathic pain, but clinical validation remains the decisive test.
Pharma & Biotech
Medical Devices & Diagnostics
Wave Neuroscience FDA clearance puts EEG-guided PTSD treatment closer to clinical adoption
Find out how Wave Neuroscience’s MeRT FDA clearance could reshape biomarker-guided PTSD treatment and precision psychiatry.
Medical Devices & Diagnostics
Medtronic’s SPR Therapeutics deal signals a sharper move into earlier chronic pain intervention
Chronic pain care needs non-opioid options. Medtronic’s SPR Therapeutics deal tests whether temporary PNS can scale beyond niche adoption.
Medical Devices & Diagnostics
Why BlueWind Medical’s $47.8m raise matters for the next phase of UUI treatment
UUI devices have clinical momentum. BlueWind Medical’s next challenge is proving Revi can scale through access, reimbursement, and workflow adoption.
Pharma & Biotech
Why electroCore, Inc.’s first PTSD patient enrollment could become a more important 2026 medtech catalyst than it first appears
electroCore, Inc. advances gammaCore in PTSD with first patient enrollment. Read why this 2026 medtech catalyst could matter more than it appears.
Medical Devices & Diagnostics
How electroCore, Inc. is strengthening the clinical case for bioelectronic medicine in trauma-related brain injury
electroCore, Inc.’s latest data could reshape bioelectronic medicine in trauma-related brain injury. Read what clinicians and industry watchers may track next.
Medical Devices & Diagnostics
LUNA trial 2026: Spark Biomedical tests non-pharmacological device for heavy menstrual bleeding
Spark Biomedical launches LUNA Phase II trial evaluating wearable auricular neurostimulation for heavy menstrual bleeding. What the study design reveals.
Medical Devices & Diagnostics
FDA clears compact SPRY TMS system: can Soterix Medical disrupt the depression treatment market?
Soterix Medical wins FDA clearance for SPRY TMS in treatment-resistant major depression. What the clearance means for the neuromodulation market. Read the analysis.
Medical Devices & Diagnostics
Diamond Lake Clinic’s EXOMIND rollout signals shifting priorities in noninvasive depression treatment
Diamond Lake Clinic introduces EXOMIND for depression care. Find out what this shift means for neuromodulation, evidence standards, and mental health treatment models.
Medical Devices & Diagnostics
Nalu Medical’s wearable-powered PNS shows strong 24-month durability in COMFORT RCT
Nalu’s PNS system shows 85% responder rate at 24 months. Find out what this long-term data means for neuromodulation’s future.